Applied machine learning in Alzheimer's disease research: omics, imaging, and clinical data

Author:

Li Ziyi1ORCID,Jiang Xiaoqian2,Wang Yizhuo1,Kim Yejin2

Affiliation:

1. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.

2. School of Biomedical Informatics, The University of Texas Health Science Center, Houston, TX, U.S.A.

Abstract

Alzheimer's disease (AD) remains a devastating neurodegenerative disease with few preventive or curative treatments available. Modern technology developments of high-throughput omics platforms and imaging equipment provide unprecedented opportunities to study the etiology and progression of this disease. Meanwhile, the vast amount of data from various modalities, such as genetics, proteomics, transcriptomics, and imaging, as well as clinical features impose great challenges in data integration and analysis. Machine learning (ML) methods offer novel techniques to address high dimensional data, integrate data from different sources, model the etiological and clinical heterogeneity, and discover new biomarkers. These directions have the potential to help us better manage the disease progression and develop novel treatment strategies. This mini-review paper summarizes different ML methods that have been applied to study AD using single-platform or multi-modal data. We review the current state of ML applications for five key directions of AD research: disease classification, drug repurposing, subtyping, progression prediction, and biomarker discovery. This summary provides insights about the current research status of ML-based AD research and highlights potential directions for future research.

Publisher

Portland Press Ltd.

Subject

General Agricultural and Biological Sciences,General Biochemistry, Genetics and Molecular Biology

Reference149 articles.

1. CDC Aging Report: https://www.cdc.gov/aging/aginginfo/alzheimers.htm

2. Current and future treatments for Alzheimer's disease;Ther. Adv. Neurol. Disord.,2013

3. FDA approval of aduhelm paves a new path for Alzheimer's disease;ACS Chem. Neurosci.,2021

4. The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA;Nat. Rev. Neurol.,2021

5. The age of Alzheimer's;Age,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3